Record Revenue Growth
Revenue for the first half of FY 2024 was JPY 12.7 billion, compared to JPY 2.1 billion in the same period last year, driven by new partnerships and milestone revenues.
Core Operating Profit Turnaround
Core operating profit was JPY 1.1 billion, a significant improvement from a loss of JPY 2.7 billion in the same period last year.
Strong PIVLAZ Sales
PIVLAZ achieved JPY 6.5 billion in sales in the first half, with a target to exceed JPY 16 billion in NHI sales for the year.
Strategic Partnerships and Milestones
Entered an exclusive option to license agreement with Boehringer Ingelheim and received milestone payments from Neurocrine and AbbVie.
Robust R&D Pipeline
Nine active clinical programs in collaboration with strategic partners, including significant progress in muscarinic agonist programs.